首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1573886

过敏免疫治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Allergy Immunotherapy Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月29日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球过敏免疫治疗市场价值为 19 亿美元，预计在整个预测期内复合年增长率为 8.5%。这一增长主要是由全球过敏症盛行率不断上升所推动的，这凸显了对过敏免疫疗法等有效治疗方案的迫切需求。

推动市场扩张的一个重要因素是医疗保健支出的增加和消费者对先进治疗的认识不断增强。处方药的创新带来了更有针对性的治疗，增加了患者的可及性和便利性。研究也致力于开发可以同时针对多种过敏原的先进治疗方法，提高疗效并扩大患者的治疗选择。预计这些进步将对未来几年的过敏免疫疗法市场产生积极影响。

过敏免疫疗法，也称为低敏或脱敏，是一种旨在透过缓慢增加患者对不同过敏原的耐受性来减轻过敏症状的医疗方法。这种治疗包括透过舌下免疫治疗 (SLIT) 片剂或滴剂或皮下免疫治疗 (SCIT) 注射，使患者接触逐渐增加剂量的过敏原。

过敏免疫治疗市场根据治疗类型可分为 SCIT 和 SLIT，其中 SCIT 细分市场将在 2023 年领先市场，规模达 11 亿美元。 SCIT 已广泛使用多年，其功效已得到充分研究并为医疗保健提供者所熟悉。它有效地针对多种过敏原，包括尘螨、花粉和昆虫毒液，使其成为多种过敏患者的多功能选择。此外，众所周知 SCIT 可以诱导强烈的免疫反应，使其成为严重过敏病例的首选。

依过敏类型分类，市场包括过敏性鼻炎、气喘、皮肤过敏、食物过敏等。由于其高盛行率，过敏性鼻炎细分市场在 2023 年占据了主导市场。

从分销管道来看，市场分为医院、零售和线上药房，预计到2032年医院药房将达到21亿美元。

2023年，北美是过敏免疫治疗的最大市场，收入为7.805亿美元。这种主导地位是由于该地区发达的医疗保健系统、过敏症盛行率高以及有利的监管环境，促进了新疗法的快速采用。美国市场特别受益于强大的医疗基础设施和研究进步，确保其在过敏免疫治疗领域的持续领先地位。

产业生态系统分析
产业影响力
- 成长动力
  - 过敏性疾病的盛行率不断增加
  - 舌下剂量免疫疗法的进展
  - 扩大产品组合
- 产业陷阱与挑战
  - 治疗费用高
  - 认知度和可近性有限
成长潜力分析
监管环境
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

主要趋势
皮下免疫疗法（SCIT）
舌下免疫疗法（SLIT）
- 平板电脑
- 滴

第 6 章：市场估计与预测：按过敏类型，2021 - 2032

主要趋势
过敏性鼻炎
气喘
皮肤过敏
食物过敏
其他过敏

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

主要趋势
医院药房
零售药房
网路药房

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Adamis Pharmaceuticals Corporation
Aimmune Therapeutics, Inc.
ALK-Abello A/S
Allergy Therapeutics plc
ASIT Biotech
Circassia Pharmaceuticals plc
DESENTUM OY
DVB Technologies SA
HAL Allergy B.V.
HollisterStier Allergy
LETI Pharma
Merck KGaA
Mylan N.V.
Stallergenes Greer plc
Zhejiang Wolwo Bio-pharmaceutical Co., Ltd.

简介目录

Product Code: 11114

The Global Allergy Immunotherapy Market was valued at USD 1.9 billion in 2023 and is projected to grow at an 8.5% CAGR throughout the forecast period. This growth is largely driven by the increasing prevalence of allergies worldwide, highlighting the urgent need for effective treatment options like allergy immunotherapy.

One significant factor contributing to market expansion is the rising healthcare expenditure and growing consumer awareness regarding advanced treatments. Innovations in prescription medications have led to more targeted therapies, increasing patient accessibility and convenience. Research is also focusing on developing advanced treatments that can target multiple allergens simultaneously, enhancing efficacy and expanding treatment options for patients. Such advancements are expected to positively impact the allergy immunotherapy market in the coming years.

Allergy immunotherapy, also known as hypo-sensitization or desensitization, is a medical treatment aimed at alleviating allergic symptoms by slowly increasing a patient's tolerance to distinct allergens. This treatment involves exposing patients to gradually increasing doses of allergens, either through sublingual immunotherapy (SLIT) tablets or drops or subcutaneous immunotherapy (SCIT) injections.

The allergy immunotherapy market can be divided based on treatment type into SCIT and SLIT, with the SCIT segment leading the market in 2023, accounting for USD 1.1 billion. SCIT has been widely used for several years, making its efficacy well-studied and familiar to healthcare providers. It effectively targets a variety of allergens, including dust mites, pollens, and insect venom, making it a versatile option for patients with multiple allergies. Furthermore, SCIT is known to induce a strong immune response, making it the preferred choice for severe allergic cases.

When categorized by allergy type, the market includes allergic rhinitis, asthma, skin allergies, food allergies, and others. The allergic rhinitis segment held a dominant market share in 2023, driven by its high prevalence.

In terms of distribution channels, the market is divided into hospital, retail, and online pharmacies, with hospital pharmacies expected to reach USD 2.1 billion by 2032. Hospital pharmacies are essential for managing specialized allergy immunotherapy medications and ensuring patients receive the appropriate treatment.

North America was the largest market for allergy immunotherapy in 2023, with revenues of USD 780.5 million. This dominance is due to the region's well-developed healthcare system, high prevalence of allergies, and favorable regulatory environment, which facilitates the rapid adoption of new treatments. The U.S. market specifically benefits from strong healthcare infrastructure and research advancements, ensuring its continued leadership in the allergy immunotherapy sector.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of allergic conditions
  - 3.2.1.2 Advancements in sublingual dosage immunotherapy
  - 3.2.1.3 Expanding product portfolio
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Limited awareness and accessibility
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Subcutaneous immunotherapy (SCIT)
5.3 Sublingual immunotherapy (SLIT)
- 5.3.1 Tablets
- 5.3.2 Drops

Chapter 6 Market Estimates and Forecast, By Allergy Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Allergic rhinitis
6.3 Asthma
6.4 Skin allergy
6.5 Food allergy
6.6 Other allergies

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa